IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
INTERPACE BIOSCIENCES, INC. revenue by segment
By business segment
| Revenue | Q2 22 | Q3 15 | Q2 15 | Q1 15 | Q4 14 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | Q3 13 | Q2 13 | Q1 13 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marketing Services [Member] | – | – | – | – | – | $1.01M | $614.00K | $1.00M | – | $781.00K | $1.64M | $1.54M | – |
| Product Commercialization Services [Member] | – | – | – | – | – | $53.00K | $2.90M | $2.98M | – | $2.73M | $3.31M | $3.16M | – |
| Sales Services [Member] | – | – | – | – | – | $28.19M | $28.07M | $28.80M | – | $30.75M | $32.29M | $38.23M | – |
| Commercial Services [Member] | – | $34.12M | $34.09M | $36.20M | $27.40M | $28.22M | $31.01M | $31.83M | – | – | – | – | – |
| Interpace Diagnostics [Member] [Member] | – | $2.51M | $2.25M | $2.12M | – | $47.00K | $0 | $0 | – | – | – | – | – |
| Operating income | Q2 22 | Q3 15 | Q2 15 | Q1 15 | Q4 14 | Q3 14 | Q2 14 | Q1 14 | Q4 13 | Q3 13 | Q2 13 | Q1 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marketing Services [Member] | – | – | – | – | – | -$1.28M | -$1.68M | -$1.32M | -$2.01M | -$1.18M | -$518.00K | -$683.00K |
| Product Commercialization Services [Member] | – | – | – | – | – | -$2.19M | -$330.00K | -$224.00K | $165.00K | $441.00K | $688.00K | $572.00K |
| Sales Services [Member] | – | – | – | – | – | -$746.00K | -$509.00K | $50.00K | -$1.78M | -$1.32M | -$1.02M | $2.36M |
| Commercial Services [Member] | – | $916.00K | $0 | $1.46M | -$2.51M | -$973.00K | -$148.00K | $466.00K | – | – | – | – |
| Interpace Diagnostics [Member] [Member] | – | -$4.92M | -$5.94M | -$4.35M | – | -$2.23M | -$914.00K | -$880.00K | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Interpace Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.